 |
80 Diseases |  |
1 Trial |
|
1 Trial |  |
61 News |  |
- || Rituxan (rituximab) / Roche
Trial completion: INGRID: RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor (clinicaltrials.gov) - Aug 3, 2022
P2, N=28, Completed, Sponsor: Andres J. M. Ferreri
Unknown status --> Completed
- || Opdivo (nivolumab) / Ono Pharma, BMS
Retrospective data, Review, Journal: Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Jan 12, 2022
Nivolumab plus ipilimumab had the best PFS ranking (SUCRA: 92.3%). Second-line treatment with nivolumab plus ipilimumab provided the OS and PFS outcomes for patients with relapsed MPM.
- || Revlimid (lenalidomide) / BMS, Arenegyr (NGR-hTNF) / AGC Biologics, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, P2 data, Journal: Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. (Pubmed Central) - May 15, 2021
P2
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment of diffuse large B-cell lymphoma (DLBCL)...Herein, we report activity and safety of R-CHOP preceded by NGR-hTNF in patients with PCNSL relapsed/refractory to high-dose methotrexate-based chemotherapy enrolled in a phase 2 trial...Seventeen of the 21 patients with response to treatment received consolidation (ASCT, WBRT, and/or lenalidomide maintenance)...Further research on this innovative approach to CNS lymphomas is warranted. The trial was registered as EudraCT: 2014-001532-11.
- | Arenegyr (NGR-hTNF) / MolMed
Journal: Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling. (Pubmed Central) - Feb 7, 2020
The reduced activation of the pro survival pathways induced by NGR-hTNF correlated with the increased caspases activation and reduced cell survival. This study demonstrates that the binding of the NGR-motif to CD13 determines not only the homing of NGR-hTNF to tumor vessels, but also the increase in its antiangiogenic activity.
- | doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen
Journal: R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma. (Pubmed Central) - Jan 16, 2020
P2
The use of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could overcome these difficulties, but blood-brain barrier (BBB) penetration of related drugs is poor...In conclusion, NGR-hTNF/R-CHOP was safe in these heavily-pretreated patients. NGR-hTNF enhanced vascular permeability specifically in tumoral/peritumoral areas, which resulted in fast and sustained responses.
- || Arenegyr (NGR-hTNF) / MolMed
Clinical, Journal, Combination therapy, Checkpoint inhibition: Targeting tumor vasculature with TNF leads effector T cells to the tumor and enhances therapeutic efficacy of immune checkpoint blockers in combination with ACT. (Pubmed Central) - Nov 19, 2019
NGR-hTNF enhanced vascular permeability specifically in tumoral/peritumoral areas, which resulted in fast and sustained responses. Targeting the tumor vasculature with low-dose TNF in association with ACT may represent a novel strategy for enhancing T-cell infiltration in tumors and overcoming resistance to immune checkpoint blockers.
- | Arenegyr (NGR-hTNF) / MolMed
Clinical, Journal: NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. (Pubmed Central) - Sep 28, 2019
Targeting the tumor vasculature with low-dose TNF in association with ACT may represent a novel strategy for enhancing T-cell infiltration in tumors and overcoming resistance to immune checkpoint blockers. NGR-hTNF plus doxorubicin showed manageable toxicity and promising activity in patients with relapsed SCLC.
- ||||| Arenegyr (NGR-hTNF) / Molmed, Rituxan (rituximab) / Roche, Biogen
Interesting paper on relapsed CNS #lymphoma treated with R-CHOP after increased vessels permeability TNF alpha coupled with NGR (NGR-hTNF), a peptide targeting CD13+ vessels by Andre Ferreri et al in @BloodJournal https://t.co/5kjo6sm57W (Twitter) - Jul 21, 2019
- | Arenegyr (NGR-hTNF) / Molmed
Clinical, P3 data, Journal, Combination therapy: NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. (Pubmed Central) - Apr 11, 2019
P3
The study did not meet its primary endpoint. The hypothesis-generating findings from the subgroup analyses deserve a confirmatory randomised trial because patients who rapidly progress after first-line treatment have a poor prognosis.
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Enrollment change, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Jan 16, 2019
P2, N=137, Completed, Sponsor: MolMed S.p.A.
The hypothesis-generating findings from the subgroup analyses deserve a confirmatory randomised trial because patients who rapidly progress after first-line treatment have a poor prognosis. Active, not recruiting --> Completed | N=100 --> 137
- || Arenegyr (NGR-hTNF) / AGC Biologics
New P2 trial, Combination therapy: NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) (clinicaltrials.gov) - Jan 15, 2019
P2, N=14, Completed, Sponsor: MolMed S.p.A.
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Combination therapy, Metastases: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer (clinicaltrials.gov) - Sep 27, 2018
P2, N=37, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | N=100 --> 137 Active, not recruiting --> Completed
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Sep 27, 2018
P2, N=119, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2016 | Trial primary completion date: Jun 2016 --> Dec 2016
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 27, 2018
P2, N=121, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2016 | Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Mar 2017 | Trial primary completion date: Jun 2016 --> Mar 2017
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Trial primary completion date: Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour (clinicaltrials.gov) - Aug 29, 2018
P1, N=48, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Mar 2017 | Trial primary completion date: Jun 2016 --> Mar 2017 Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Feb 2017 | Trial primary completion date: Jun 2016 --> Feb 2017
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Combination therapy, Metastases: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. (clinicaltrials.gov) - Aug 29, 2018
P2, N=69, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Feb 2017 | Trial primary completion date: Jun 2016 --> Feb 2017 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> May 2016
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: NGR007: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma (clinicaltrials.gov) - Aug 29, 2018
P2, N=28, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> May 2016 Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2015 | Trial primary completion date: Jun 2016 --> Nov 2015
- | Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Aug 29, 2018
P2, N=100, Active, not recruiting, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2015 | Trial primary completion date: Jun 2016 --> Nov 2015 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018
- ||||||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial primary completion date, Metastases: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed (clinicaltrials.gov) - Dec 22, 2017
P3, N=400, Completed, Sponsor: MolMed S.p.A.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2016 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2017
- || Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Oct 22, 2015
P2, N=100, Recruiting, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Jun 2016 --> Dec 2016
- |||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed (clinicaltrials.gov) - Oct 22, 2015
P3, N=390, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- || Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=102, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date: Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour (clinicaltrials.gov) - Oct 22, 2015
P1, N=48, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=37, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: NGR007: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=28, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- || Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (clinicaltrials.gov) - Apr 14, 2015
P2, N=100, Recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Jun 2013 --> Jun 2016
- |||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Metastases: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed (clinicaltrials.gov) - Apr 14, 2015
P3, N=390, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Jun 2013 --> Jun 2016 Trial primary completion date: Nov 2013 --> Dec 2015
- || Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=102, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Nov 2013 --> Dec 2015 Trial primary completion date: Sep 2013 --> Dec 2015
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date: Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour (clinicaltrials.gov) - Apr 14, 2015
P1, N=48, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Sep 2013 --> Dec 2015 Trial primary completion date: Jun 2013 --> Dec 2015
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=37, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Jun 2013 --> Dec 2015 Trial primary completion date: Feb 2013 --> Dec 2015
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial primary completion date, Combination therapy, Metastases: NGR007: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma (clinicaltrials.gov) - Apr 14, 2015
P2, N=28, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Feb 2013 --> Dec 2015 Trial primary completion date: Jan 2013 --> Dec 2015
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Trial primary completion date, Combination therapy: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Apr 6, 2015
P2, N=124, Active, not recruiting, Sponsor: MolMed S.p.A.
Trial primary completion date: Jan 2013 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. (clinicaltrials.gov) - Apr 6, 2015
P2, N=96, Active, not recruiting, Sponsor: MolMed S.p.A.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Combination therapy, Metastases: NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 28, 2014
P2, N=24, Completed, Sponsor: MolMed S.p.A.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Jun 2016 Active, not recruiting --> Completed
- |||| Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Metastases: Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma (clinicaltrials.gov) - May 28, 2014
P2, N=57, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Metastases: Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - May 28, 2014
P2, N=40, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion: Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC) (clinicaltrials.gov) - May 28, 2014
P2, N=46, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion: Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor (clinicaltrials.gov) - May 28, 2014
P1, N=22, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment change, Combination therapy: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Jan 27, 2013
P2, N=124, Recruiting, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed N=100 --> 124
- ||||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Metastases: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed (clinicaltrials.gov) - Jan 27, 2013
P3, N=390, Active, not recruiting, Sponsor: MolMed S.p.A.
N=100 --> 124 Recruiting --> Active, not recruiting
- ||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed, Combination therapy, Metastases: NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 27, 2013
P2, N=102, Active, not recruiting, Sponsor: MolMed S.p.A.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment change, Metastases: NGR-TNF in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 19, 2012
P1, N=70, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting N=30 --> 70
- Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Metastases: NGR-TNF in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 19, 2012
P1, N=70, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=30 --> 70 Active, not recruiting --> Completed
- |||| Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment open, Combination therapy: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Jan 2, 2012
P2, N=124, Recruiting, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Arenegyr (NGR-hTNF) / AGC Biologics
Enrollment closed: Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour (clinicaltrials.gov) - Jan 2, 2012
P1, N=48, Active, not recruiting, Sponsor: MolMed S.p.A.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting